Advanced Therapy Medicinal Products Market Forecast 2026–2030: Market Size, Trends And Growth Opportunities
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Advanced Therapy Medicinal Products Market Value Growth And Long-Term Outlook
The advanced therapy medicinal products market has experienced significant expansion in recent years. This market is set to increase from $51.34 billion in 2025 to $61.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.6%. Historically, its development has been linked to factors such as the restricted availability of advanced therapy products, a reliance on conventional biologics, developing regulatory structures, the high expense of gene and cell therapies, and insufficient distribution networks.
The advanced therapy medicinal products market is projected to experience substantial growth in the coming years. It is forecast to expand to $124.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.3%. This growth during the forecast period is driven by factors such as technological advancements in gene editing and stem cell therapies, increasing investment in personalized medicine, the rising prevalence of rare and chronic diseases, the expansion of hospital pharmacy and specialty clinic networks, and the integration of AI-driven manufacturing and automation processes. Key trends anticipated in this period include the rising adoption of autologous and allogeneic therapies, the broadening scope of gene editing and viral vector technologies, an increasing focus on rare disease treatments, the integration of automation in therapy manufacturing, and growing collaborations between hospitals and specialty clinics.
Get A Free Sample Report With In-Depth Market Insights:
Advanced Therapy Medicinal Products Market Industry Drivers: What’s Behind The Revenue Growth?
The anticipated expansion of the advanced therapy medicinal products market going forward is linked to a growing need for personalized medicine. This medical approach involves tailoring treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The increasing demand for personalized medicine primarily arises from the rising prevalence of chronic diseases, as it allows for customized treatments that enhance outcomes and reduce side effects for individual patients. Advanced therapy medicinal products facilitate personalized medicine by offering bespoke treatments, such as gene, cell, and tissue-engineered therapies, which target the unique genetic and biological profiles of individual patients. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the escalating demand for personalized medicine is a key driver for the growth of the advanced therapy medicinal products market.
Advanced Therapy Medicinal Products Market Segment Outlook: Which Categories Are Growing Fastest?
The advanced therapy medicinal products market covered in this report is segmented –
1) By Product: Somatic Cell Therapy Medicinal Products, Tissue Engineered Medicinal Products, Gene Therapy Medicinal Products
2) By Technology: Gene Editing Technologies, Viral Vector Technology, Stem Cell Technology, Automation And Artificial Intelligence-Driven Processes
3) By Application: Muscular Dystrophies, Alzheimer’s, Hemophilia, Cystic Fibrosis, Other Applications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Somatic Cell Therapy Medicinal Products: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, Dendritic Cell Therapy, Natural Killer Cell Therapy
2) By Tissue Engineered Medicinal Products: Autologous Tissue-Engineered Products, Allogeneic Tissue-Engineered Products, Scaffold-Based Tissue Engineering, Scaffold-Free Tissue Engineering, Skin Substitutes
3) By Gene Therapy Medicinal Products: In Vivo Gene Therapy, Ex Vivo Gene Therapy, Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Gene Editing Therapies
#Advanced Therapy Medicinal Products Market Growth Trends: What’s Shaping The Future Outlook?
Major companies engaged in the advanced therapy medicinal products (ATMP) market are concentrating on the development of innovative treatments, including gene editing cell therapies, to provide targeted and potentially curative solutions for conditions like β thalassemia and sickle cell disease. These gene editing cell therapies involve the collection of a patient’s hematopoietic stem cells and the precise ex vivo modification of their genome, often leveraging CRISPR Cas9 technology to correct harmful mutations or activate beneficial genetic pathways. This offers a personalized alternative to traditional allogeneic bone marrow transplantation, which depends on donor matching and carries risks such as graft versus host disease. For example, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, secured US Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel, or exa cel), a CRISPR Cas9-based gene editing cell therapy designed for transfusion-dependent β thalassemia. The therapy employs autologous CD34+ stem and progenitor cells, edits the erythroid-specific BCL11A enhancer to elevate fetal hemoglobin levels, and has demonstrated sustained clinical improvements, with the potential to achieve transfusion independence for many patients and significantly reduce or eliminate the need for regular blood transfusions.
Advanced Therapy Medicinal Products Market Leading Companies And Competitive Benchmarking
Major companies operating in the advanced therapy medicinal products market are F. Hoffmann-La Roche Limited., Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited., Lonza Group AG, Catalent Inc., BioMarin Pharmaceutical Inc., AGC Biologics Inc., ViaCyte Inc., Rentschler Biopharma SE, JCR Pharmaceuticals Co. Ltd., Vericel Corporation, UniQure N.V., Fate Therapeutics Inc., WuXi Advanced Therapies Inc., Celonic Group AG, Pharmicell Co. Ltd., Magenta Therapeutics Inc, MEDIPOST Co. Ltd., Kolon TissueGene Inc
View The Full Advanced Therapy Medicinal Products Market Report:
Advanced Therapy Medicinal Products Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the advanced therapy medicinal products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
